It's obvious that the company has a good shot at returning to growth.

With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage ...

Q4 2025 Management View Christopher Viehbacher, President, CEO & Director, opened by stating, "We finished the year strongly ...

Biogen Inc (NASDAQ:BIIB) reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company ...

Biogen BIIB will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

(Reuters) -Biogen beat Wall Street estimates for third-quarter profit, helped by better-than-expected sales of some of its multiple sclerosis treatments. The company, however, cut its annual profit ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in ...

Biogen on Wednesday reported third-quarter revenue and adjusted earnings that topped expectations while raising its full-year profit guidance, as sales of its breakthrough Alzheimer's drug, Leqembi, ...